Terms: = Breast cancer AND MAP3K1, ENSG00000095015, 4214, Q13233, MEKK1, MEKK, MAPKKK1 AND Treatment
25 results:
1. Prognostic Factors Associated with Tumor Recurrence and Overall Survival in Soft Tissue Sarcomas of the Extremities in a Colombian Reference cancer Center.
Díaz Casas SE; Villacrés JM; Lehmann Mosquera C; García Mora M; Mariño Lozano I; Ángel Aristizábal J; Suarez Rodríguez R; Duarte Torres CA; Sánchez Pedraza R
Curr Oncol; 2024 Mar; 31(4):1725-1738. PubMed ID: 38668034
[No Abstract] [Full Text] [Related]
2. The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.
Vellichirammal NN; Tan YD; Xiao P; Eudy J; Shats O; Kelly D; Desler M; Cowan K; Guda C
Hum Genomics; 2023 Jul; 17(1):64. PubMed ID: 37454130
[TBL] [Abstract] [Full Text] [Related]
3. Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Guo S; Jin F; Zheng A
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37283514
[TBL] [Abstract] [Full Text] [Related]
4. Profiling the Somatic Mutational Landscape of breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.
Ding YC; Song H; Adamson AW; Schmolze D; Hu D; Huntsman S; Steele L; Patrick CS; Tao S; Hernandez N; Adams CD; Fejerman L; Gardner K; Nápoles AM; Pérez-Stable EJ; Weitzel JN; Bengtsson H; Huang FW; Neuhausen SL; Ziv E
Cancer Res; 2023 Aug; 83(15):2600-2613. PubMed ID: 37145128
[TBL] [Abstract] [Full Text] [Related]
5. Early Triple-Negative breast cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression.
Yeong J; Goh D; Tan TJ; Tan B; Sivaraj H; Koh V; Tatt Lim JC; Joseph CR; Ye J; Yong Tay TK; Chan Lau M; Chan JY; Ng C; Iqbal J; Teh BT; Dent RA; Tan PH
Mod Pathol; 2023 Apr; 36(4):100056. PubMed ID: 36788078
[TBL] [Abstract] [Full Text] [Related]
6. Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis.
Guan Y; Shen G; Fang Q; Xin Y; Huo X; Li J; Zhao F; Ren D; Liu Z; Li Z; Zhao J
Clin Exp Med; 2023 Jun; 23(2):245-254. PubMed ID: 35304677
[TBL] [Abstract] [Full Text] [Related]
7. Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes.
Asleh K; Negri GL; Spencer Miko SE; Colborne S; Hughes CS; Wang XQ; Gao D; Gilks CB; Chia SKL; Nielsen TO; Morin GB
Nat Commun; 2022 Feb; 13(1):896. PubMed ID: 35173148
[TBL] [Abstract] [Full Text] [Related]
8. Long non-coding RNA LRRC75A-AS1 facilitates triple negative breast cancer cell proliferation and invasion via functioning as a ceRNA to modulate BAALC.
Li S; Wu D; Jia H; Zhang Z
Cell Death Dis; 2020 Aug; 11(8):643. PubMed ID: 32811810
[TBL] [Abstract] [Full Text] [Related]
9. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract] [Full Text] [Related]
10. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
[TBL] [Abstract] [Full Text] [Related]
11. Association between FGFR1 copy numbers, map3k1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
[TBL] [Abstract] [Full Text] [Related]
12. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
Liang X; Briaux A; Becette V; Benoist C; Boulai A; Chemlali W; Schnitzler A; Baulande S; Rivera S; Mouret-Reynier MA; Bouvet LV; De La Motte Rouge T; Lemonnier J; Lerebours F; Callens C
J Hematol Oncol; 2018 Oct; 11(1):124. PubMed ID: 30305115
[TBL] [Abstract] [Full Text] [Related]
13. Effect of
Nassan MA; Soliman MM; Ismail SA; El-Shazly S
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30126855
[TBL] [Abstract] [Full Text] [Related]
14. Polymorphisms of ESR1, UGT1A1, HCN1, map3k1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Kuo SH; Yang SY; You SL; Lien HC; Lin CH; Lin PH; Huang CS
Oncotarget; 2017 Mar; 8(13):20925-20938. PubMed ID: 28178648
[TBL] [Abstract] [Full Text] [Related]
15. Mutational Profile of Metastatic breast cancers: A Retrospective Analysis.
Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
[TBL] [Abstract] [Full Text] [Related]
16. Silencing map3k1 expression through RNA interference enhances paclitaxel-induced cell cycle arrest in human breast cancer cells.
Hu P; Huang Q; Li Z; Wu X; Ouyang Q; Chen J; Cao Y
Mol Biol Rep; 2014 Jan; 41(1):19-24. PubMed ID: 24253898
[TBL] [Abstract] [Full Text] [Related]
17. Sequence analysis of mutations and translocations across breast cancer subtypes.
Banerji S; Cibulskis K; Rangel-Escareno C; Brown KK; Carter SL; Frederick AM; Lawrence MS; Sivachenko AY; Sougnez C; Zou L; Cortes ML; Fernandez-Lopez JC; Peng S; Ardlie KG; Auclair D; Bautista-Piña V; Duke F; Francis J; Jung J; Maffuz-Aziz A; Onofrio RC; Parkin M; Pho NH; Quintanar-Jurado V; Ramos AH; Rebollar-Vega R; Rodriguez-Cuevas S; Romero-Cordoba SL; Schumacher SE; Stransky N; Thompson KM; Uribe-Figueroa L; Baselga J; Beroukhim R; Polyak K; Sgroi DC; Richardson AL; Jimenez-Sanchez G; Lander ES; Gabriel SB; Garraway LA; Golub TR; Melendez-Zajgla J; Toker A; Getz G; Hidalgo-Miranda A; Meyerson M
Nature; 2012 Jun; 486(7403):405-9. PubMed ID: 22722202
[TBL] [Abstract] [Full Text] [Related]
18. Whole-genome analysis informs breast cancer response to aromatase inhibition.
Ellis MJ; Ding L; Shen D; Luo J; Suman VJ; Wallis JW; Van Tine BA; Hoog J; Goiffon RJ; Goldstein TC; Ng S; Lin L; Crowder R; Snider J; Ballman K; Weber J; Chen K; Koboldt DC; Kandoth C; Schierding WS; McMichael JF; Miller CA; Lu C; Harris CC; McLellan MD; Wendl MC; DeSchryver K; Allred DC; Esserman L; Unzeitig G; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Leitch M; Hunt K; Olson J; Tao Y; Maher CA; Fulton LL; Fulton RS; Harrison M; Oberkfell B; Du F; Demeter R; Vickery TL; Elhammali A; Piwnica-Worms H; McDonald S; Watson M; Dooling DJ; Ota D; Chang LW; Bose R; Ley TJ; Piwnica-Worms D; Stuart JM; Wilson RK; Mardis ER
Nature; 2012 Jun; 486(7403):353-60. PubMed ID: 22722193
[TBL] [Abstract] [Full Text] [Related]
19. breast cancer genome-wide association studies: there is strength in numbers.
Fanale D; Amodeo V; Corsini LR; Rizzo S; Bazan V; Russo A
Oncogene; 2012 Apr; 31(17):2121-8. PubMed ID: 21996731
[TBL] [Abstract] [Full Text] [Related]
20. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.
Hadad S; Iwamoto T; Jordan L; Purdie C; Bray S; Baker L; Jellema G; Deharo S; Hardie DG; Pusztai L; Moulder-Thompson S; Dewar JA; Thompson AM
Breast Cancer Res Treat; 2011 Aug; 128(3):783-94. PubMed ID: 21655990
[TBL] [Abstract] [Full Text] [Related]
[Next]
